Molecular profiling of tumor tissue using targeted clinical proteomics

我们的结果表明，我们能够检测到新诊断的非转移性癌症患者血液中的肿瘤残留蛋白。对单个患者的肿瘤进行深入的蛋白质组学分析，以进一步阐明特定的分子表型。一组可能的标记物正在用高通量技术进行研究，使用合适的免疫分析方法来测试其对患有这种特殊实体器官肿瘤的更大规模的患者队列的普遍适用性。这种方法有助于最大限度地提高治疗效果，减少毒性，并试图减少医疗经济负担。进一步的研究表明，利用患者肿瘤的薄组织方法，为发现与个体患者癌症相关的关键蛋白质提供了一个平台。其中许多都是毒品目标。这一新方法与免疫组织化学的组织和时间要求几乎相同，但具有互补性。一个主要目标是为临床试验提供一种新的研究工具，使用这种在蛋白质水平上进行分子图谱分析的实用方法，使用患者实际肿瘤的薄组织切片。

Our results have shown the ability to detect tumor residing proteins in the blood of a patient with a newly diagnosed non-metastatic cancer. In depth proteomic profiling of an individual patient's tumor for further elucidation of the particular molecular phenotype. A panel of putative markers are under investigation with high throughput techniques employing suitable immunoassays to test for general applicability to a much larger patient cohorts with this particular solid organ tumor. Such an approach facilitates maximization of therapeutic efficacy, minization of toxicities, and an attempt to reduce medical economic burdens. Further studies have now shown that a thin-tissue approach utilizing patient tumors, provide a discovery platform for key proteins involved in the individual patient's cancer. Many of these are drug targets. This new approach is nearly identical to the tissue and time requirements of IHC (immunohistochemistry), but is complementary. A major goal is to provide a new research tool for clinical trials, using this practical approach of molecular profiling on a protein level, with thin tissue sections from the patient's actual tumor.